AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
Symbicort contains the active medications budesonide and formoterol. Budesonide belongs to a drug class called corticosteroids. Formoterol belongs to a drug class called long-acting beta2 agonists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results